Dipyridamole
Back to searchMolecule Structure
Scientific Name
Dipyridamole
Description of the Drug
Dipyridamole is a phosphodiesterase inhibitor used to prevent postoperative thromboembolic events.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00975
http://www.drugbank.ca/drugs/DB00975
Brand Name(s)
Attia, Cerebrovase 100, Cerebrovase 25, Dipyridamole, Iv persantine, Modaplate, Ofcram pr, Persantin, Persantine, Persantin ret, Pyridantin, Vasyrol
Company Owner(s)
Glenmark Pharmaceuticals Sa Switzerland, Lannett Co Inc, Watson Laboratories Inc, Impax Laboratories Inc, Fresenius Kabi Usa Llc, Oxford Pharmaceuticals Llc, Athenex Inc, Par Pharmaceutical Inc, Sun Pharmaceutical Industries Ltd, Zydus Pharmaceuticals Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Equilibrative nucleoside transporter 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL1997 |
3′,5′-cyclic phosphodiesterase | PROTEIN FAMILY | INHIBITOR | CHEMBL2363066 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL16119 | |||||||
PharmGKB | PA449367 | |||||||
Human Metabolome Database | HMDB0015110 | |||||||
WDI | DR9712008 | DR9505426 | DR9505427 | DR9505428 | DR9505429 | RX-RE-92 | DIPYRIDAM | |
DrugBank | DB00975 | |||||||
PubChem: Thomson Pharma | 14811101 | |||||||
PubChem | 3108 | |||||||
Mcule | MCULE-3112669573 | |||||||
NMRShiftDB | 20208396 | |||||||
LINCS | LSM-3927 | |||||||
Nikkaji | J8.585E | |||||||
PDBe | H9F | |||||||
BindingDB | 23620 | |||||||
EPA CompTox Dashboard | DTXSID6040668 | |||||||
DrugCentral | 924 | |||||||
Brenda | 138816 | 154381 | 69114 | 229398 | 1192 | 229397 | 70635 | 153397 |
ChemicalBook | CB6731869 | |||||||
Guide to Pharmacology | 4807 | |||||||
GSRS | 48320a72-182a-4a53-94e4-002d2e4bee0d | |||||||
rxnorm | PERSANTINE | DIPYRIDAMOLE | ||||||
PubChem: Drugs of the Future | 81044336 | |||||||
ChEBI | 4653 | |||||||
NIH Clinical Collection | SAM002264609 | |||||||
ZINC | ZINC000000643046 |